These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 26575959

  • 1. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J, Kamar N, Mengelle C, Allal A, Sallusto F, Doumerc N, Game X, Congy-Jolivet N, Esposito L, Debiol B, Rostaing L.
    Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
    [Abstract] [Full Text] [Related]

  • 2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 3. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A, Iwai T, Uchida J.
    Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O, Mathew JM, Shetty A, Bontha SV, Maluf DG, El Kassis Y, Park SH, Han J, Ansari MJ, Leventhal JR, Mas V, Gallon L.
    PLoS One; 2019 Mar; 14(5):e0216300. PubMed ID: 31136582
    [Abstract] [Full Text] [Related]

  • 12. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ, Graviss EA, Nguyen DT, Kuten SA, Patel SJ, Gaber L, Gaber AO.
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects.
    Renner FC, Dietrich H, Bulut N, Celik D, Freitag E, Gaertner N, Karoui S, Mark J, Raatz C, Weimer R, Feustel A.
    Transplant Proc; 2013 May; 45(4):1608-10. PubMed ID: 23726630
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
    Felipe CR, Oliveira NI, Hannun PG, de Paula MI, Tedesco-Silva H, Medina-Pestana JO.
    Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen.
    Geddes CC, Gunson R, Mazonakis E, Wan R, Thomson L, Clancy M, Carman WF.
    Transpl Infect Dis; 2011 Apr; 13(2):109-16. PubMed ID: 21457419
    [Abstract] [Full Text] [Related]

  • 20. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.